Tetrahydroaminoacridine, 3,4 diaminopyridine and physostigmine: direct comparison of effects on memory in aged primates.
The effects of tetrahydroaminoacridine (THA), 3,4 diaminopyridine (3,4 DAP) and physostigmine were evaluated for their ability to reduce memory impairments in aged, test-sophisticated cebus monkeys (18 to 26 years old). Several doses of each drug were tested (PO) in each of ten different monkeys, allowing for direct and extensive comparison of each drug's efficacy in this model. The results of this comparative test revealed several potentially interesting findings: (1) all drugs produced improvement in a portion of the monkeys tested; (2) as in many past tests with aged monkeys and humans, wide variations in most effective dose, per subject, were observed; (3) different monkeys responded more effectively to one drug than another; and (4) under these tightly controlled conditions, physostigmine produced the most reliable and robust effects (p less than 0.005), in more monkeys, than did either THA (p less than 0.05) or 3,4 DAP (p less than 0.10).
Bartus
R T
RT
Department of CNS Research, Lederle Laboratories, Pearl River, NY 10965.
Dean
R L
RL
D015761:4-Aminopyridine / Q000031:analogs & derivatives*; D000375:Aging / Q000502:physiology*; D000077770:Amifampridine; D000631:Aminopyridines / Q000627:therapeutic use*; D000818:Animals; D002427:Cebidae / Q000502:physiology*; D002428:Cebus / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D008297:Male; D008569:Memory Disorders / Q000188:drug therapy / Q000503:physiopathology*; D010830:Physostigmine / Q000627:therapeutic use*
D000631:Aminopyridines; D010830:Physostigmine; D015761:4-Aminopyridine; D000077770:Amifampridine